Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: Bridging molecular studies and clinical trials

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 8, 2013, Pages 1128-1142

  Vallano, A ^a,b   Fernandez Duenas V ^b   Garcia Negredo G ^b   Quijada, M A ^a   Simon C P ^a   Cuffi M L ^b   Carbonell, L ^b   Sanchez S ^b   Arnau, J M ^a,b   Ciruela, F ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

AFQ056; Clinical trial; GPCR oligomerization; mGlu5R; Parkinson's disease

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL) PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL) ETHYNYL] PYRIDINE; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR; ADX10059; ADX48621; AMANTADINE; CALMODULIN; CARBIDOPA PLUS LEVODOPA; DIPRAGLURANT; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DYNORPHIN; ENKEPHALIN; EPHRIN; FENOBAM; MAVOGLURANT; METABOTROPIC RECEPTOR 5; NP 2009; OLIGOMER; OPTINEURIN; PROTEIN KINASE C; RASEGLURANT; SUBSTANCE P; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; GRM5 PROTEIN, HUMAN;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSKINESIA; HUMAN; MULTICENTER STUDY (TOPIC); NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STRIATE CORTEX; ANIMAL; CLINICAL TRIAL (TOPIC); CORPUS STRIATUM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; CORPUS STRIATUM; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84891706526     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: None     Document Type: Article

References (115)

1. Meldrum, B.S. Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J. Nutr., 2000, 130, 1007S-1015S.
2. Robinson, M.B.; Coyle, J.T. Glutamate and related acidic excitatory neurotransmitters: From basic science to clinical application. FASEB J., 1987, 1, 446-455.
3. Lau, A.; Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 2010, 460, 525-542.
4. Coyle, J.T.; Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science, 1993, 262, 689-695.
5. Traynelis, S.F.; Wollmuth, L.P.; McBain, C.J.; Menniti, F.S.; Vance, K.M.; Ogden, K.K.; Hansen, K.B.; Yuan, H.; Myers, S.J.; Dingledine, R. Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol. Rev., 2010, 62, 405-496.
6. Pin, J.P.; Duvoisin, R. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology, 1995, 34, 1-26.
7. Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci., 1994, 17, 31-108.
8. Ferraguti, F.; Crepaldi, L.; Nicoletti, F. Metabotropic glutamate 1 receptor: Current concepts and perspectives. Pharmacol. Rev., 2008, 60, 536-581.
9. Pin, J.P.; Waeber, C.; Prezeau, L.; Bockaert, J.; Heinemann, S.F. Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in xenopus oocytes. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 10331-10335.
10. Grandes, P.; Mateos, J.M.; Ruegg, D.; Kuhn, R.; Knopfel, T. Differential cellular localization of three splice variants of the mGluR1 metabotropic glutamate receptor in rat cerebellum. Neuroreport, 1994, 5, 2249-2252.
11. Romano, C.; Smout, S.; Miller, J.K.; O'Malley, K.L. Developmental regulation of metabotropic glutamate receptor 5b protein in rodent brain. Neuroscience, 2002, 111, 693-698.
12. Corti, C.; Clarkson, R.W.; Crepaldi, L.; Sala, C.F.; Xuereb, J.H.; Ferraguti, F. Gene structure of the human metabotropic glutamate receptor 5 and functional analysis of its multiple promoters in neuroblastoma and astroglioma cells. J. Biol. Chem., 2003, 278, 33105-33119.
13. Romano, C.; Sesma, M.A.; McDonald, C.T.; O'Malley, K.; Van den Pol, A.N.; Olney, J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol., 1995, 355, 455-469.
14. Lujan, R.; Nusser, Z.; Roberts, J.D.; Shigemoto, R.; Somogyi, P. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci., 1996, 8, 1488-1500.
15. Mannaioni, G.; Marino, M.J.; Valenti, O.; Traynelis, S.F.; Conn, P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci., 2001, 21, 5925-5934.
16. Musante, V.; Neri, E.; Feligioni, M.; Puliti, A.; Pedrazzi, M.; Conti, V.; Usai, C.; Diaspro, A.; Ravazzolo, R.; Henley, J.M.; Battaglia, G.; Pittaluga, A. Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings. Neuropharmacology, 2008, 55, 474-482.
17. Gubellini, P.; Pisani, A.; Centonze, D.; Bernardi, G.; Calabresi, P. Metabotropic glutamate receptors and striatal synaptic plasticity: Implications for neurological diseases. Prog. Neurobiol., 2004, 74, 271-300.
18. Conquet, F.; Bashir, Z.I.; Davies, C.H.; Daniel, H.; Ferraguti, F.; Bordi, F.; Franz-Bacon, K.; Reggiani, A.; Matarese, V.; Conde, F. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature, 1994, 372, 237-243.
19. Gubellini, P.; Saulle, E.; Centonze, D.; Bonsi, P.; Pisani, A.; Bernardi, G.; Conquet, F.; Calabresi, P. Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology, 2001, 40, 839-846.
20. Sung, K.W.; Choi, S.; Lovinger, D.M. Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J. Neurophysiol., 2001, 86, 2405-2412.
21. Bonsi, P.; Pisani, A.; Bernardi, G.; Calabresi, P. Stimulus frequency, calcium levels and striatal synaptic plasticity. Neuroreport, 2003, 14, 419-422.
22. Gubellini, P.; Saulle, E.; Centonze, D.; Costa, C.; Tropepi, D.; Bernardi, G.; Conquet, F.; Calabresi, P. Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology, 2003, 44, 8-16.
23. Lang, A.E.; Lozano, A.M. Parkinson's disease. first of two parts. N. Engl. J. Med., 1998, 339, 1044-1053.
24. Poewe, W.; Mahlknecht, P. The clinical progression of parkinson's disease. Parkinsonism Relat. Disord., 2009, 15 Suppl 4, S28-32.
25. Hely, M.A.; Morris, J.G.; Reid, W.G.; Trafficante, R. Sydney multicenter study of parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov. Disord., 2005, 20, 190-199.
26. Meissner, W.G.; Frasier, M.; Gasser, T.; Goetz, C.G.; Lozano, A.; Piccini, P.; Obeso, J.A.; Rascol, O.; Schapira, A.; Voon, V.; Weiner, D.M.; Tison, F.; Bezard, E. Priorities in parkinson's disease research. Nat. Rev. Drug Discov., 2011, 10, 377-393.
27. Reiner, A.; Medina, L.; Haber, S.N. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans. Neuroscience, 1999, 88, 775-793.
28. Steiner, H.; Gerfen, C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain Res., 1998, 123, 60-76.
29. Ceballos-Baumann, A.O.; Obeso, J.A.; Vitek, J.L.; Delong, M.R.; Bakay, R.; Linazasoro, G.; Brooks, D.J. Restoration of thalamocortical activity after posteroventral pallidotomy in parkinson's disease. Lancet, 1994, 344, 814.
30. Vitek, J.L.; Ashe, J.; DeLong, M.R.; Alexander, G.E. Physiologic properties and somatotopic organization of the primate motor thalamus. J. Neurophysiol., 1994, 71, 1498-1513.
31. Betchen, S.A.; Kaplitt, M. Future and current surgical therapies in parkinson's disease. Curr. Opin. Neurol., 2003, 16, 487-493.
32. Limousin, P.; Martinez-Torres, I. Deep brain stimulation for parkinson's disease. Neurotherapeutics, 2008, 5, 309-319.
33. Rouse, S.T.; Marino, M.J.; Bradley, S.R.; Awad, H.; Wittmann, M.; Conn, P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: Implications for treatment of parkinson's disease and related disorders. Pharmacol. Ther., 2000, 88, 427-435.
34. Wittmann, M.; Marino, M.J.; Bradley, S.R.; Conn, P.J. GABAergic inhibition of substantia nigra pars reticulata projection neurons is modulated by metabotropic glutamate receptors. Soc Neurosci Abstr, 1999, 25, 446.
35. Fredriksson, R.; Lagerstrom, M.C.; Lundin, L.G.; Schioth, H.B. The G-protein-coupled receptors in the human genome form five main families. phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
36. Enz, R. Metabotropic glutamate receptors and interacting proteins: Evolving drug targets. Curr. Drug Targets, 2012, 13, 145-156.
37. Cabello, N.; Remelli, R.; Canela, L.; Soriguera, A.; Mallol, J.; Canela, E.I.; Robbins, M.J.; Lluis, C.; Franco, R.; McIlhinney, R.A.; Ciruela, F. Actin-binding protein alpha-actinin-1 interacts with the metabotropic glutamate receptor type 5b and modulates the cell surface expression and function of the receptor. J. Biol. Chem., 2007, 282, 12143-12153.
38. Enz, R. The actin-binding protein filamin-A interacts with the metabotropic glutamate receptor type 7. FEBS Lett., 2002, 514, 184-188.
39. Cheng, S.; Zhang, J.; Zhu, P.; Ma, Y.; Xiong, Y.; Sun, L.; Xu, J.; Zhang, H.; He, J. The PDZ domain protein CAL interacts with mGluR5a and modulates receptor expression. J. Neurochem., 2010, 112, 588-598.
40. Tu, J.C.; Xiao, B.; Yuan, J.P.; Lanahan, A.A.; Leoffert, K.; Li, M.; Linden, D.J.; Worley, P.F. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron, 1998, 21, 717-726.
41. Paquet, M.; Asay, M.J.; Fam, S.R.; Inuzuka, H.; Castleberry, A.M.; Oller, H.; Smith, Y.; Yun, C.C.; Traynelis, S.F.; Hall, R.A. The PDZ scaffold NHERF-2 interacts with mGluR5 and regulates receptor activity. J. Biol. Chem., 2006, 281, 29949-29961.
42. Kitano, J.; Kimura, K.; Yamazaki, Y.; Soda, T.; Shigemoto, R.; Nakajima, Y.; Nakanishi, S. Tamalin, a PDZ domain-containing protein, links a protein complex formation of group 1 metabotropic glutamate receptors and the guanine nucleotide exchange factor cytohesins. J. Neurosci., 2002, 22, 1280-1289.
43. Ferreira, L.T.; Dale, L.B.; Ribeiro, F.M.; Babwah, A.V.; Pampillo, M.; Ferguson, S.S. Calcineurin inhibitor protein (CAIN) attenuates group I metabotropic glutamate receptor endocytosis and signaling. J. Biol. Chem., 2009, 284, 28986-28994.
44. Minakami, R.; Jinnai, N.; Sugiyama, H. Phosphorylation and calmodulin binding of the metabotropic glutamate receptor subtype 5 (mGluR5) are antagonistic in vitro. J. Biol. Chem., 1997, 272, 20291-20298.
45. Piccinin, S.; Cinque, C.; Calo, L.; Molinaro, G.; Battaglia, G.; Maggi, L.; Nicoletti, F.; Melchiorri, D.; Eusebi, F.; Massey, P.V.; Bashir, Z.I. Interaction between ephrins and mGlu5 metabotropic glutamate receptors in the induction of long-term synaptic depression in the hippocampus. J. Neurosci., 2010, 30, 2835-2843.
46. Canela, L.; Fernandez-Duenas, V.; Albergaria, C.; Watanabe, M.; Lluis, C.; Mallol, J.; Canela, E.I.; Franco, R.; Lujan, R.; Ciruela, F. The association of metabotropic glutamate receptor type 5 with the neuronal Ca2+-binding protein 2 modulates receptor function. J. Neurochem., 2009, 111, 555-567.
47. Wang, H.; Westin, L.; Nong, Y.; Birnbaum, S.; Bendor, J.; Brismar, H.; Nestler, E.; Aperia, A.; Flajolet, M.; Greengard, P. Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science, 2009, 326, 1554-1557.
48. Anborgh, P.H.; Godin, C.; Pampillo, M.; Dhami, G.K.; Dale, L.B.; Cregan, S.P.; Truant, R.; Ferguson, S.S. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J. Biol. Chem., 2005, 280, 34840-34848.
49. Mao, L.M.; Liu, X.Y.; Zhang, G.C.; Chu, X.P.; Fibuch, E.E.; Wang, L.S.; Liu, Z.; Wang, J.Q. Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo. Neuropharmacology, 2008, 55, 403-408.
50. Croci, C.; Sticht, H.; Brandstatter, J.H.; Enz, R. Group I metabotropic glutamate receptors bind to protein phosphatase 1C. mapping and modeling of interacting sequences. J. Biol. Chem., 2003, 278, 50682-50690.
51. Ishikawa, K.; Nash, S.R.; Nishimune, A.; Neki, A.; Kaneko, S.; Nakanishi, S. Competitive interaction of seven in absentia homolog-1A and Ca2+/calmodulin with the cytoplasmic tail of group 1 metabotropic glutamate receptors. Genes Cells, 1999, 4, 381-390.
52. Doumazane, E.; Scholler, P.; Zwier, J.M.; Eric, T.; Rondard, P.; Pin, J.P. A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. FASEB J., 2011, 25, 66-77.
53. Romano, C.; Yang, W.L.; O'Malley, K.L. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem., 1996, 271, 28612-28616.
54. Gonzalez-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; Lopez-Gimenez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.
55. Schroder, H.; Wu, D.F.; Seifert, A.; Rankovic, M.; Schulz, S.; Hollt, V.; Koch, T. Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor. Neuropharmacology, 2009, 56, 768-778.
56. Ferre, S.; Karcz-Kubicha, M.; Hope, B.T.; Popoli, P.; Burgueno, J.; Gutierrez, M.A.; Casado, V.; Fuxe, K.; Goldberg, S.R.; Lluis, C.; Franco, R.; Ciruela, F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA, 2002, 99, 11940-11945.
57. Cabello, N.; Gandia, J.; Bertarelli, D.C.; Watanabe, M.; Lluis, C.; Franco, R.; Ferre, S.; Lujan, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D (2) and adenosine A (2a) receptors form higherorder oligomers in living cells. J. Neurochem., 2009, 109, 1497-1507.
58. C.R. Gerfen, Basal ganglia, in: G. Paxinos (Ed.), The Rat Nervous System, Elsevier Academic Press, Amsterdam, 2004, pp. 445-508.
59. Sesack, S.R.; Grace, A.A. Cortico-basal ganglia reward network: Microcircuitry. Neuropsychopharmacology, 2010, 35, 27-47.
60. Smith, A.D.; Bolam, J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci., 1990, 13, 259-265.
61. Ferre, S.; Fredholm, B.B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci., 1997, 20, 482-487.
62. Hettinger, B.D.; Lee, A.; Linden, J.; Rosin, D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol., 2001, 431, 331-346.
63. Rosin, D.L.; Hettinger, B.D.; Lee, A.; Linden, J. Anatomy of adenosine A2A receptors in brain: Morphological substrates for integration of striatal function. Neurology, 2003, 61, S12-S18.
64. Ferre, S.; Borycz, J.; Goldberg, S.R.; Hope, B.T.; Morales, M.; Lluis, C.; Franco, R.; Ciruela, F.; Cunha, R. Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J. Integr. Neurosci., 2005, 4, 445-464.
65. Popoli, P.; Pezzola, A.; Torvinen, M.; Reggio, R.; Pintor, A.; Scarchilli, L.; Fuxe, K.; Ferre, S. The selective mGlu (5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D (2) receptors in the rat striatum: Interactions with adenosine A (2a) receptors. Neuropsychopharmacology, 2001, 25, 505-513.
66. Kachroo, A.; Orlando, L.R.; Grandy, D.K.; Chen, J.F.; Young, A.B.; Schwarzschild, M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci., 2005, 25, 10414-10419.
67. Coccurello, R.; Breysse, N.; Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats. Neuropsychopharmacology, 2004, 29, 1451-1461.
68. Ciruela, F.; Vilardaga, J.P.; Fernandez-Duenas, V. Lighting up multiprotein complexes: Lessons from GPCR oligomerization. Trends Biotechnol., 2010, 28, 407-415.
69. Ferre, S.; Agnati, L.F.; Ciruela, F.; Lluis, C.; Woods, A.S.; Fuxe, K.; Franco, R. Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module. Brain Res. Rev., 2007, 55, 55-67.
70. Ferre, S.; Ciruela, F.; Quiroz, C.; Lujan, R.; Popoli, P.; Cunha, R.A.; Agnati, L.F.; Fuxe, K.; Woods, A.S.; Lluis, C.; Franco, R. Adenosine receptor heteromers and their integrative role in striatal function. ScientificWorldJournal, 2007, 7, 74-85.
71. Ferre, S.; Agnati, L.F.; Ciruela, F.; Lluis, C.; Woods, A.S.; Fuxe, K.; Franco, R. Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module. Brain Res. Rev., 2007, 55, 55-67.
72. Fuxe, K.; Marcellino, D.; Borroto-Escuela, D.O.; Guescini, M.; Fernandez-Duenas, V.; Tanganelli, S.; Rivera, A.; Ciruela, F.; Agnati, L.F. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther., 2010, 16, e18-e42.
73. Cotzias, G.C.; Van Woert, M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 1967, 276, 374-379.
74. Poewe, W. Treatments for parkinson disease--past achievements and current clinical needs. Neurology, 2009, 72, S65-S73.
75. Rascol, O.; Brooks, D.J.; Korczyn, A.D.; De Deyn, P.P.; Clarke, C.E.; Lang, A.E. A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa. 056 study group. N. Engl. J. Med., 2000, 342, 1484-1491.
76. Ferre, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 7238-7241.
77. Sweatt, J.D. The neuronal MAP kinase cascade: A biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem., 2001, 76, 1-10.
78. Ferre, S.; O'Connor, W.T.; Fuxe, K.; Ungerstedt, U. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain. J. Neurosci., 1993, 13, 5402-5406.
79. Cho, K.; Bashir, Z.I. Cooperation between mglu receptors: A depressing mechanism? Trends Neurosci., 2002, 25, 405-411.
80. Alagarsamy, S.; Marino, M.J.; Rouse, S.T.; Gereau, R.W., 4th; Heinemann, S.F.; Conn, P.J. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat. Neurosci., 1999, 2, 234-240.
81. Vallano, A.; Fernandez-Duenas, V.; Pedros, C.; Arnau, J.M.; Ciruela, F. An update on adenosine A2A receptors as drug target in parkinson's disease. CNS Neurol. Disord. Drug Targets, 2011, 10, 659-669.
82. Bonsi, P.; Cuomo, D.; Picconi, B.; Sciamanna, G.; Tscherter, A.; Tolu, M.; Bernardi, G.; Calabresi, P.; Pisani, A. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in parkinson's disease. Amino Acids, 2007, 32, 189-195.
83. Fox, S.H.; Brotchie, J.M.; Lang, A.E. Non-dopaminergic treatments in development for parkinson's disease. Lancet Neurol., 2008, 7, 927-938.
84. Chase, T.N.; Oh, J.D. Striatal dopamine-and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci., 2000, 23, S86-S91.
85. Dawson, T.M.; Ko, H.S.; Dawson, V.L. Genetic animal models of parkinson's disease. Neuron, 2010, 66, 646-661.
86. Terzioglu, M.; Galter, D. Parkinson's disease: Genetic versus toxininduced rodent models. FEBS J., 2008, 275, 1384-1391.
87. Schwarting, R.K.; Huston, J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. analysis of functional deficits, recovery and treatments. Prog. Neurobiol., 1996, 50, 275-331.
88. Breysse, N.; Baunez, C.; Spooren, W.; Gasparini, F.; Amalric, M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci., 2002, 22, 5669-5678.
89. Breysse, N.; Amalric, M.; Salin, P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci., 2003, 23, 8302-8309.
90. De Leonibus, E.; Manago, F.; Giordani, F.; Petrosino, F.; Lopez, S.; Oliverio, A.; Amalric, M.; Mele, A. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of parkinson's disease. Neuropsychopharmacology, 2009, 34, 729-738.
91. Chen, L.; Zhang, Q.J.; Liu, J.; Wang, S.; Ali, U.; Gui, Z.H.; Wang, Y. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons. Brain Res., 2009, 1286, 192-200.
92. Johnson, K.A.; Conn, P.J.; Niswender, C.M. Glutamate receptors as therapeutic targets for parkinson's disease. CNS Neurol. Disord. Drug Targets, 2009, 8, 475-491.
93. Zigmond, M.J.; Berger, T.W.; Grace, A.A.; Stricker, E.M. Compensatory responses to nigrostriatal bundle injury. studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol. Chem. Neuropathol., 1989, 10, 185-200.
94. Samadi, P.; Gregoire, L.; Morissette, M.; Calon, F.; Hadj Tahar, A.; Dridi, M.; Belanger, N.; Meltzer, L.T.; Bedard, P.J.; Di Paolo, T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging, 2008, 29, 1040-1051.
95. Levandis, G.; Bazzini, E.; Armentero, M.T.; Nappi, G.; Blandini, F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of parkinson's disease. Neurobiol. Dis., 2008, 29, 161-168.
96. Johnston, T.H.; Fox, S.H.; McIldowie, M.J.; Piggott, M.J.; Brotchie, J.M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl) ethynyl]pyridine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of parkinson's disease. J. Pharmacol. Exp. Ther., 2010, 333, 865-873.
97. Mela, F.; Marti, M.; Dekundy, A.; Danysz, W.; Morari, M.; Cenci, M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of parkinson's disease. J. Neurochem., 2007, 101, 483-497.
98. Papa, S.M.; Chase, T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol., 1996, 39, 574-578.
99. Bibbiani, F.; Oh, J.D.; Kielaite, A.; Collins, M.A.; Smith, C.; Chase, T.N. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol., 2005, 196, 422-429.
100. Nicoletti, F.; Bockaert, J.; Collingridge, G.L.; Conn, P.J.; Ferraguti, F.; Schoepp, D.D.; Wroblewski, J.T.; Pin, J.P. Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology, 2011, 60, 1017-1041.
101. Lea, P.M., 4th; Faden, A.I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev., 2006, 12, 149-166.
102. Yashuara, A.; Chaki, S. Metabotropic glutamate receptors: Potential drugs targets for psychiatric disorders. Open Med Chem, 2010, 4, 20-36.
103. Melancon, B.J.; Hopkins, C.R.; Wood, M.R.; Emmitte, K.A.; Niswender, C.M.; Christopoulos, A.; Conn, P.J.; Lindsley, C.W. Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem., 2012, 55, 1445-1464.
104. Levenga, J.; Hayashi, S.; de Vrij, F.M.; Koekkoek, S.K.; van der Linde, H.C.; Nieuwenhuizen, I.; Song, C.; Buijsen, R.A.; Pop, A.S.; Gomezmancilla, B.; Nelson, D.L.; Willemsen, R.; Gasparini, F.; Oostra, B.A. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis., 2011, 42, 311-317.
105. Jacquemont, S.; Curie, A.; des Portes, V.; Torrioli, M.G.; Berry-Kravis, E.; Hagerman, R.J.; Ramos, F.J.; Cornish, K.; He, Y.; Paulding, C.; Neri, G.; Chen, F.; Hadjikhani, N.; Martinet, D.; Meyer, J.; Beckmann, J.S.; Delange, K.; Brun, A.; Bussy, G.; Gasparini, F.; Hilse, T.; Floesser, A.; Branson, J.; Bilbe, G.; Johns, D.; Gomez-Mancilla, B. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med., 2011, 3, 64ra1.
106. Kenny, P.J. Emerging therapeutic targets for the treatment of nicotine addiction. Expert Rev Clin Pharmacol, 2009, 2, 221-225.
107. Blondeau, K. Treatment of gastro-esophageal reflux disease: The new kids to block. Neurogastroenterol. Motil., 2010, 22, 836-840.
108. Berg, D.; Godau, J.; Trenkwalder, C.; Eggert, K.; Csoti, I.; Storch, A.; Huber, H.; Morelli-Canelo, M.; Stamelou, M.; Ries, V.; Wolz, M.; Schneider, C.; Di Paolo, T.; Gasparini, F.; Hariry, S.; Vandemeulebroecke, M.; Abi-Saab, W.; Cooke, K.; Johns, D.; Gomez-Mancilla, B. AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Mov. Disord., 2011, 26, 1243-1250.
109. Stocchi, F.; Destee, A.; Hattori, N.; Hauser, R.A.; Lang, A.E.; Poewe, W.; Rascol, O.; Stacy, M.; Tolosa, E.; Trenkwalder, C.; Gao, H.; Nagel, J.; Gomez-Mancilla, B.; Merschhemke, M.; Tekin, S.; Abi-Saab, W. A 13-week, double-blind, placebo-controlled study of AFQ056, a metabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesia. Mov. Dis. Soc. Meeting, 2011, late breaking abstract LB12.
110. Kumar, R.; Hauser, R.; Mostillo, J.; Dronanraju, N.; Graf, A.; Kenney, C.; Merschhemke, M. A 6-week, double-blind, multicenter RCT in Parkinson's disease patients to explore the efficacy and safety of AFQ056 when combined with increased dose of L-dopa. Mov Disor, 2012, 27 (Suppl. 1), S126.
111. Colosimo, C.; Martinez-Martin, P.; Fabbrini, G.; Hauser, R.A.; Merello, M.; Miyasaki, J.; Poewe, W.; Sampaio, C.; Rascol, O.; Stebbins, G.T.; Schrag, A.; Goetz, C.G. Task force report on scales to assess dyskinesia in parkinson's disease: Critique and recommendations. Mov. Disord., 2010, 25, 1131-1142.
112. Chakraborty, A.; Ufer, M.; Bhad, P.; Vandemeulebroecke, M.; Gomez-Mancilla, B.; Bell, D.; Winter, S. Lack of pharmacokinetic interaction between the novel mGluR5 antagonist AFQ056 and levodopa/carbidopa in healthy volunteers. Mov Disor, 2012, 27 (Suppl 1), 456.
113. Ciruela, F.; Fernandez-Duenas, V.; Llorente, J.; Borroto-Escuela, D.; Cuffi, M.L.; Carbonell, L.; Sanchez, S.; Agnati, L.F.; Fuxe, K.; Tasca, C.I. G protein-coupled receptor oligomerization and brain integration: Focus on adenosinergic transmission. Brain Res., 2012, 1476, 86-95.
114. Hernandez-Lopez, S.; Tkatch, T.; Perez-Garci, E.; Galarraga, E.; Bargas, J.; Hamm, H.; Surmeier, D.J. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J. Neurosci., 2000, 20, 8987-8995.
115. Ciruela, F.; Gomez-Soler, M.; Guidolin, D.; Borroto-Escuela, D.O.; Agnati, L.F.; Fuxe, K.; Fernandez-Duenas, V. Adenosine receptor containing oligomers: Their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim. Biophys. Acta, 2011, 1808, 1245-1255.